In last trading session, Summit Therapeutics Inc (NASDAQ:SMMT) saw 3.31 million shares changing hands with its beta currently measuring -1.08. Company’s recent per share price level of $23.06 trading at $1.46 or 6.76% at ring of the bell on the day assigns it a market valuation of $17.00B. That closing price of SMMT’s stock is at a discount of -46.96% from its 52-week high price of $33.89 and is indicating a premium of 90.89% from its 52-week low price of $2.10.
For Summit Therapeutics Inc (SMMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.06 in the current quarter.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Upright in the green during last session for gaining 6.76%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $23.06 price level, adding 0.3% to its value on the day. Summit Therapeutics Inc’s shares saw a change of 29.22% in year-to-date performance and have moved 17.83% in past 5-day. Summit Therapeutics Inc (NASDAQ:SMMT) showed a performance of 4.34% in past 30-days.
Wall Street analysts have assigned a consensus price target of 36 to the stock, which implies a rise of 35.94% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would jump 0.26% in reaching the projected high whereas dropping to the targeted low would mean a gain of 0.26% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 70.17% while estimates for its earnings growth in next 5 years are of 15.48%.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
BAKER BROS. ADVISORS LP is the top institutional holder at SMMT for having 23.22 million shares of worth $181.13 million. And as of 2024-06-30, it was holding 3.2804 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 8.82 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2566 of outstanding shares, having a total worth of $68.78 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.43 shares of worth $79.1 million or 0.47% of the total outstanding shares. The later fund manager was in possession of 2.79 shares on Dec 31, 2024 , making its stake of worth around $64.4 million in the company or a holder of 0.38% of company’s stock.
